Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
TX-103 by Fuzhou Tcelltech Biological Science and Technology for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
TX-103 is under clinical development by Fuzhou Tcelltech Biological Science and Technology and currently in Phase I for Recurrent Glioblastoma...